# First-in-Human Single and Multiple Dose of GLPG1690

> **NCT02179502** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GLPG1690 single ascending doses
- **DRUG:** Placebo single ascending doses
- **DRUG:** GLPG1690, multiple ascending doses, oral suspension
- **DRUG:** Placebo, multiple ascending doses, oral suspension

## Key facts

- **NCT ID:** NCT02179502
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2014-11
- **Final completion:** 2014-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2015-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02179502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02179502, "First-in-Human Single and Multiple Dose of GLPG1690". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02179502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*